Filing Flows › BioMarin Pharmaceutical (BMRN) › Q1 2025
BioMarin Pharmaceutical (BMRN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 2, 2025
BioMarin Pharmaceutical (BMRN) reported revenue of $745M for the first quarter 2025 (Q1 2025), +15% from a year earlier and -0.3% from the quarter before. Operating margin was 30.0%, net earnings $186M (24.9% of revenue).
BioMarin Pharmaceutical, Q1 2025: revenue $745M (+15% year over year), operating margin 30.0%, net earnings $186M, operating cash flow $174M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $745M | -0.3% | +15% |
| Operating profit | $224M | +39% | +153% |
| Net earnings | $186M | +49% | +109% |
| Operating cash flow | $174M | -6% | +271% |
| Free cash flow | $158M | -5% | +655% |
What changed
Revenue was $745.1M in Q1 2025, up 15% year over year and roughly flat from the previous quarter. VOXZOGO was the largest line at 29% of revenue. VOXZOGO added $60.9M year over year (up 40%), 63% of the total change. KUVAN declined 30%.
Operating profit was $223.9M, a 30.0% margin (up 16.4 points year over year). Of the extra revenue versus a year earlier, 141% reached operating profit, above the 14% margin then. Total costs fell 7% while revenue rose 15%. The fastest-growing cost line was Cost of revenue (+21%). Net earnings were $185.7M, up 109% year over year. The effective tax rate was 22.0%.
Operating cash flow was $174.4M (up 271% year over year), 94% of net earnings. Non-cash charges added back $22.1M of depreciation and amortization and $37.7M of share-based compensation. Working capital and other items used $71.1M. Capital expenditures of $16.8M left free cash flow of $157.6M.
Questions
What was BioMarin Pharmaceutical's revenue in the first quarter 2025?
BioMarin Pharmaceutical (BMRN) reported revenue of $745M for the first quarter 2025 (Q1 2025), +15% from a year earlier and -0.3% from the quarter before.
Was BioMarin Pharmaceutical profitable in the first quarter 2025?
Operating profit was $224M (30.0% of revenue) and net earnings $186M.